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Summary
Objective: To investigate the effect of oxcarbazepine against standard antiepileptic
drug therapy (carbamazepine and valproate) on cognitive function in children and
adolescents (aged 6 to <17 years) with newly diagnosed partial seizures.
Methods: A multicentre, open-label, randomised, active-control, three-arm, paral-
lel-group, 6-month study. The primary cognitive variable, the Computerized Visual
Searching Task (CVST), assessed mental information processing speed and attention.
Secondary variables included additional tests assessing psychomotor speed, alertness,
memory and learning, and non-verbal intelligence.
Results: Of 112 patients randomised, 99 completed the study. The dropout rate was
11.6%; 13 patients discontinued due to adverse events (n = 5) or unsatisfactory
therapeutic effect (n = 8). Mean CVST time decreased in all groups, indicating an
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improvement of mental processing speed and no cognitive impairment in any treat-
ment group. No statistically significant difference was observed between oxcarba-
zepine and combined carbamazepine/valproate. Analysis of secondary variables did
not show statistically significant differences between oxcarbazepine, carbamazepine
and valproate. Analysis of intelligence test results showed that the number of correct
answers increased at end point in all groups. The percentage of patients remaining
seizure free throughout treatment was comparable across all groups (oxcarbazepine
58%; carbamazepine 46%; valproate 54%; carbamazepine/valproate 50%). The most
common adverse events were fatigue and headache for oxcarbazepine, fatigue and
rash for carbamazepine, and headache, increased appetite and alopecia for valpro-
ate.
Conclusion: Oxcarbazepine treatment over 6months does not display any differential
effects on cognitive function and intelligence in children and adolescents with newly
diagnosed partial seizures relative to standard antiepileptic drug therapy. No impair-
ment in cognitive function was observed in any treatment group over a 6-month
period.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Children with epilepsy have an increased risk of
developing cognitive impairment. Several factors
contribute to this, including the effect of the sei-
zures themselves, EEG abnormalities and psychoso-
cial issues.1—3 In addition, antiepileptic drugs (AEDs)
may adversely affect cognitive functioning in these
patients.2,4—6 A recent survey assessing the impact
of AEDs on cognitive functioning reported that 56%
of patients blamed their medication, either solely
(14%) or in combination with their epilepsy (42%),
for their cognitive impairment.7
The major cognitive effects associated with AEDs
in patients with epilepsy are impaired attention,
vigilance, and mental and psychomotor speed.6,8
Although these effects are usually offset by the
therapeutic benefit of AEDs in seizure reduction,
they are of special concern in children, as they can
impact negatively on learning, school performance
and psychosocial interactions.4,9 However, there are
few adequately designed clinical studies to date
aimed at examining the differential effect of AEDs
on cognitive function in children with epilepsy,
particularly among the newer agents.2
Oxcarbazepine is a newer AED, structurally
related to carbamazepine with a more favourable
pharmacokinetic profile and an improved tolerabil-
ity profile.10,11 Clinical experience indicates that
oxcarbazepine is a well tolerated and effective
AED for the treatment of adults and children with
partial seizures with or without secondarily general-
ised seizures.12—17
Theeffects of oxcarbazepineoncognitive function
have previously been evaluated in two studies in
healthy volunteers and in three studies in adult
patients with epilepsy.18—21 In a double-blind, pla-
cebo-controlled, crossover study in healthy volun-teers,19 the effects of two doses of oxcarbazepine
(300 mg/day and 600 mg/day) on cognitive function
andpsychomotor performancewereassessed.Oxcar-
bazepine improved performance on a focused atten-
tion task and increased manual writing speed, and
had no effect on long-term memory processes. In a
comparative study in healthy volunteers, oxcarbaze-
pine treatment was shown to induce less cognitive
slowing than carbamazepine.22 Three comparative
monotherapy studies have also evaluated the effects
of oxcarbazepine on cognitive function (intelligence,
learning andmemory, attention, psychomotor speed,
verbal span, visuospatial construction) in newly diag-
nosed adult patients with epilepsy compared with
carbamazepine, valproate, or phenytoin.18,20,21 In
the first, an active-control study, no deterioration
in cognitive function was observed in the carbama-
zepine, valproate, or oxcarbazepine treatment
groups.21 In the study by Aikia et al., which evaluated
the effects of phenytoin and oxcarbazepine onmem-
ory, attention and psychomotor speed, no significant
differential cognitive effects were found between
treatments.18 McKee et al. reported no important
changes in cognitive function among patients treated
with oxcarbazepine who had previously been receiv-
ing carbamazepine, valproate or phenytoin.20 The
results of these studies indicate that oxcarbazepine
has no or at least minimal effects on cognitive func-
tion in adult patients with epilepsy.
However, the effects of oxcarbazepine on cogni-
tive function have not been systematically studied in
children. Carbamazepine and valproate, which are
standard AEDs indicated and widely prescribed for
the treatment of childrenandadolescentswith newly
diagnosed epilepsy, are considered to have a similar
impact on cognitive functioning in these patients.6
Consequently, these standard AEDs were chosen as
comparators. This study aimed to investigate the
672 F. Donati et al.effect of oxcarbazepine against the standard AED
therapy on cognitive function in children aged 6 to
<17 years with partial seizures. Cognitive function
was tested primarily using a test for mental proces-
sing speed and attention, and six additional tests
assessing psychomotor speed, alertness, memory
and learning, and non-verbal intelligence.23—25Methods
Study design
This was a multicentre, open-label, randomised,
active-control, three-arm, parallel-group study con-
ducted at 21 neuropaediatric and epilepsy sites in
seven European countries between December 2001
and December 2003. The study consisted of two
phases: a screening phase and a 6-month open-label
treatment phase. Patients were assigned to oxcarba-
zepine, carbamazepine or valproate in a 2:1:1 ratio.
An interactive voice response system was used to
automate the randomisation of patients to treatment
groups and within age strata. Study medication was
administered as monotherapy according to the pre-
scribing information for the respective AED. The age
limits for the study participants were selected to
include paediatric and adolescent patients in accor-
dance with the European oxcarbazepine prescribing
information and the Committee for Proprietary Med-
icinal Products guidelines. The study was conducted
in accordance with the Declaration of Helsinki.
Discussion of design
An active-control design was chosen to compare the
effects of oxcarbazepine with standard AED therapy.
Parallel groups were used to avoid carry-over
effects. To control for the confounding effects of
seizures on cognitive function during baseline,
patients were only included if they experienced
no more than two secondarily generalised partial
seizures within the 3 months prior to study com-
mencement. The patient population was a homo-
genous group of newly diagnosed patients with a
localisation-related epilepsy. Randomisation was
used to avoid bias in the assignment of patients
to treatment, increase the likelihood that patient
attributes were proportionately allocated across
treatment groups, and enhance the validity of sta-
tistical comparisons. The use of an open-label study
design seemed to be acceptable as the primary and
secondary cognitive outcome assessments were
based on an objective measurement (computerised
cognitive testing).
A treatment duration of 6 months was deemed
sufficient to evaluate the effects of treatment onseizures, tolerability, and cognition in previously
untreated children and adolescents with partial
seizures. Moreover, tests cannot be repeated before
at least 6 months have passed, to avoid any learning
of the tests.
Patients
Previously untreated male or female patients aged 6
to <17 years with a history of at least two unpro-
voked partial seizures (including all seizure subtypes
of simple and complex partial seizures and partial
seizures evolving to secondarily generalised sei-
zures) were included in the study. Patients with
more than two secondarily generalised tonic-clonic
seizures within the 3 months prior to randomisation
were excluded. In addition, patients were excluded
if they had a history of clinically relevant psychiatric
disorders (Diagnostic and Statistical Manual of Men-
tal Disorders, 4th ed.), attention deficit disorder
(minimal brain dysfunction in children), comorbid
neurological disease (other than epilepsy), or other
diseases adversely affecting cognitive abilities.
Cognitive function testing
Cognitive function (psychomotor speed and alert-
ness, mental information processing speed and
attention, memory and learning) and non-verbal
intelligence were assessed by neuropsychological
testing at Visits 1 (baseline) and 3 (after 6 months
of treatment), or at the time of premature
discontinuation, using the ‘FePsy’ computerised
neuropsychological test battery, the Rey Auditory
Verbal Learning Test (AVLT) and Raven’s Standard
Progressive Matrices for children. Neuropsycholo-
gical testing was delayed for at least 48 h after the
occurrence of a secondarily generalised seizure,
and 24 h after the occurrence of a complex partial
seizure. If benzodiazepines were prescribed for
acute seizure treatment, testing was delayed by
5 times the half-life of the respective benzodiaze-
pine (minimum 48 h).
Cognitive end points
Information processing speed (‘mental speed’) has
been identified as the most susceptible cognitive
function affected by AED treatment in general6,23,26
and the resulting mental slowing is considered to be
the most clinically relevant of potential affected
functions in children (affecting for example school
performance). Therefore, a test for assessing infor-
mation processing speed was selected as the pri-
mary cognitive variable. We used the Computerized
Visual Searching Task (CVST), which has been shown
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rately in a number of other cognitive drug studies.26
CVST
The CVST is an adaptation of Goldstein’s Visual
Searching Task, in which a centred grid pattern
has to be compared with 24 surrounding patterns,
one of which is identical to the target pattern. The
test consists of 24 trials and gives an indication of
the speed of information processing and perceptual
mental strategies. The test score is the total aver-
age searching time of correct answers in seconds
(variable 1).
Secondary variables included six additional cogni-
tive tests assessing psychomotor speed and alertness
(measuredwith a finger-tapping task and visual reac-
tion time), mental information processing speed and
attention (evaluated by binary choice reaction time)
andmemory and learning (assessed by recognition of
word and figures and the AVLT). Intelligence was also
assessed using a non-verbal test for intelligence:
Raven’s Standard Progressive Matrices.25
Psychomotor speed and alertness
The finger-tapping task measures motor speed and
motor fluency for the index finger of the dominant
(variable 2) and non-dominant hand (variable 3)
separately, in average number of taps for five con-
secutive trials.
Simple reaction-timemeasurementwasmeasured
using visual stimuli (white square on the screen)
presented at random intervals by the computer.
These tests measure activation/alertness; a strong
motor speed component is involved. The test score is
the reaction time in milliseconds for the dominant
(variable 4) and the non-dominant (variable 5) hand.
Mental information processing speed and
attention
The binary choice reaction test introduces a deci-
sion component. The patient has to react differen-
tially to a red square presented on the left side of
the screen than to a green square presented on the
right side. Reaction time reflects motor speed and
the decision-making process. The test score is the
reaction time in milliseconds (variable 6).
Memory and learning
Recognition of words and figures involved test
stimuli presented simultaneously during a learning
phase. Six words and four figures are presented,
with a presentation time of 1 s per item. After a
delay of 2 s, the screen shows one of these words/
figures between distracters. The target item has to
be recognised. The test score is the number correct
out of 24 (variable 7 and variable 8).The Rey AVLTmeasures memory span and learning
strategies. Fifteenwords are presented on tape (this
test is not presented by computer and not part of
the ‘FePsy’ test system) and have to be recalled on
five consecutive trials. After 20 min, long-term
recall is requested. The test score is the number
correct out of 75 (immediate recall; variable 9) or
out of 15 (delayed recall; variable 10).
Intelligence test
Intelligence is assessed using Raven’s Standard Pro-
gressive Matrices.25 The Raven’s test is a short test
for intelligence based on visual spatial tasks.
Neuropsychological testing of five of the seven
cognitive tests was conducted with the ‘FePsy’
computerised neuropsychological test battery for
children. The tests, test procedures, and validation
of the tests (i.e. the evaluation of correlations with
standard neuropsychological tests) have been
described elsewhere.24,26—28 In addition, the AVLT
non-computerised neuropsychological test was
used, as well as the Raven.25 All tests control for
retesting effects either by presenting parallel items
at retesting or by presenting items randomly, to
avoid any ‘learning’ of the test. Retesting effects
have been reported as minimal.24,26—28
Efficacy and overall treatment satisfaction
Even though evaluating the efficacy of the study
medication was not the primary aim of this study,
the occurrence of seizures was recorded at baseline,
during the open-label treatment phase, and at study
completion, and classified according to the Interna-
tional Classification of Epileptic Seizures.29,30 In
addition, an overall assessment of treatment satis-
faction among investigators, patients, and parents/
carers was recorded using a 4-point scale ranging
from ‘poor’ to ‘very good’.
Safety evaluation
The safety assessment was based on the frequency
of adverse events and the number of laboratory
values that fell outside predetermined notable
ranges. AED serum levels were not measured during
this study.
Statistical analyses
The per-protocol patient population, comprising all
randomised patients who received at least one dose
of study medication and who performed a CVST
assessment at baseline and at the completion of
the 6-month open-label treatment phase, was used
for the primary analysis. The intent-to-treat patient
674 F. Donati et al.population included all randomised patients who
received at least one dose of study medication
and from whom a neuropsychological measurement
(any of the seven tests) was obtained before and
after randomisation. Seizure frequency evaluations
and overall treatment satisfaction were analysed
using the intent-to-treat population. All randomised
patients who received study medication were used
for the safety analysis.
The primary comparison was made between the
CVST results for the oxcarbazepine group and the
combined carbamazepine and valproate treatment
group in the per-protocol patient population. Dif-
ferences between treatment groups on the CVSTand
cognitive end points were tested using an analysis of
covariance (ANCOVA), with end point test score as
the dependent variable, country and age group as
factors, and baseline score as covariate. Changes in
intelligence test scores (from baseline to end point)
and comparisons between treatment groups were
analysed using a Van Elteren test (Cochran-Mantel-
Haenszel test with modified Ridit Scores) stratified
by age group.
Sample size and power considerations
The sample size calculationwas based on the primary
cognitive variable (CVST). To have a power of at least
90% to detect a meaningful difference between
treatment groups (oxcarbazepine versus standard
AED) of approximately three-quarter standard devia-Table 1 Patient demographics including baseline seizure a
Characteristic OXC (n = 55) CBZ (n =
Male, n (%) 21 (38.2) 16 (57.1
Age (years)
Median (range) 10 (6—16) 10 (6—1
Age group, n (%)
6 to <12 years 40 (72.7) 17 (60.7
12 to <17 years 15 (27.3) 11 (39.3
Weight (kg)a
Median (range) 37.3 (18.5—82.0) 40.2 (20
ILAE seizure classification, n (%)
Simple partial 23 (41.8) 9 (32.1
Complex partial 23 (41.8) 17 (60.7
Partial evolving into
secondarily GTC
31 (56.4) 16 (57.1
ILAE epilepsy classification, n (%)b
Idiopathic 31 (56.4) 16 (57.1
Symptomatic 9 (16.4) 2 (7.1)
Cryptogenic 14 (25.5) 10 (35.7
CBZ = carbamazepine; GTC = generalised tonic-clonic; ILAE = Int
VPA = valproate.
a OXC, n = 54; VPA, n = 28; CBZ/VPA, n = 56.
b Information on one patient in the oxcarbazepine group relatingtion (as seen in previous studies with this test, asses-
sing for example the effect of phenytoin)4 78
evaluable patients were necessary. Taking into
account an expected 40% dropout rate, approxi-
mately 130 patientswere planned for randomisation.Results
Patient demographics and disposition
Patient demographics are presented in Table 1. Of
the 112 patients randomised, 99 completed the
study and 97 (per-protocol population) were eligible
for the primary analysis. Due to the low dropout rate
of 11.6%, recruitment was stopped after 112
patients had been randomised. Thirteen patients
discontinued due to adverse events (n = 5) or unsa-
tisfactory therapeutic effect (n = 8). Treatment
groups were well balanced with respect to their
baseline demographic characteristics. Age, weight,
and sex distribution were comparable between
treatment groups. Moreover, the distribution of
seizure types was similar for the oxcarbazepine
group and the combined carbamazepine/valproate
treatment group (Table 1), indicating that the
patient population was homogenous. Similarly,
there was no difference in epilepsy type between
the oxcarbazepine and combined carbamazepine/
valproate treatment groups (Table 1). Mean daily
doses (S.D.) during the 4 weeks prior to assessmentsnd epilepsy classification (safety population)
28) VPA (n = 29) CBZ/VPA (n = 57)
) 14 (48.3) 30 (52.6)
6) 9 (6—15) 9 (6—16)
) 23 (79.3) 40 (70.2)
) 6 (20.7) 17 (29.8)
.9—65.5) 33.3 (22.0—61.0) 35.5 (20.9—65.5)
) 12 (41.4) 21 (36.8)
) 15 (51.7) 32 (56.1)
) 11 (37.9) 27 (47.4)
) 17 (58.6) 33 (57.9)
4 (13.8) 6 (10.5)
) 8 (27.6) 18 (31.6)
ernational League Against Epilepsy; OXC = oxcarbazepine;
to epilepsy classification was not provided by the investigator.
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.at 6 months were 19.6 (6.4) mg/kg for oxcarbaze-
pine, 14.4 (3.6) mg/kg for carbamazepine, and 20.7
(7.5) mg/kg for valproate.
Cognitive end points
Mean CVST time decreased in all three treatment
groups (indicating an improvement in mental infor-
mation processing speed) and similar CVST out-
comes were found in the two age groups,
indicating that there was no cognitive impairment
in any treatment group. The primary end point
comparison of the CVST results did not show a
significant difference between oxcarbazepine and
combined carbamazepine/valproate (Tables 2 and
3; p = 0.195). The quite large baseline imbalance in
the CVST (mean values: oxcarbazepine 19.9, car-
bamazepine 16.7, valproate 14.7, carbamazepine/
valproate 15.7) was adjusted for in the model for
the end point analysis (mean values at end point:
oxcarbazepine 16.0, carbamazepine 14.9, valpro-
ate 14.5, carbamazepine/valproate 14.7). A
numerical benefit for the combined treatment
group of 1.3 using the raw mean values is reversed
to a numerical benefit of 1.1 for oxcarbazepine by
applying the ANCOVA model. Due to the baseline
imbalance, results have to be interpreted cau-
tiously, but the overall conclusion remains that
there were no meaningful differences between
the treatment groups.
Analysis of the secondary neuropsychological
variables (psychomotor speed and alertness, mem-
ory and learning, and attention) did not show any
significant differences between oxcarbazepine and
combined carbamazepine/valproate, or between
carbamazepine and valproate (Tables 2 and 3).
Analysis of the intelligence test results (Raven’s
Standard Progressive Matrices) showed that the
number of correct answers increased at end point
in all treatment groups, indicating improvement of
intelligence scores. However, there were no statis-
tically significant differences between treatment
groups (Table 4).
Efficacy and overall treatment satisfaction
Although efficacy was not formally analysed in this
study, the percentage of patients in the intent-to-
treat population who were seizure free throughout
the 6-month treatment phase was comparable
across all treatment groups (oxcarbazepine 58%;
carbamazepine 46%; valproate 54%; carbamaze-
pine/valproate 50%). Assessment of overall treat-
ment satisfaction showed that 84% of investigators,
82% of patients, and 86% of parents/carers in the
oxcarbazepine group rated their treatment as
676
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Table 3 Analysis of cognitive variables for each treatment group (per-protocol population, n = 97)
Oxcarbazepine (n = 47) Carbamazepine (n = 26) Valproate (n = 24)
Mean baseline
value (S.D.)
Mean change from
baseline (S.D.)
Mean baseline
value (S.D.)
Mean change from
baseline (S.D.)
Mean baseline
value (S.D.)
Mean change from
baseline (S.D.)
Psychomotor speed and alertness
Finger-tapping task
Dominant hand 48.91 (8.2) 0.15 (3.4)" 49.13 (8.7) 1.03 (5.0)# 48.53 (7.3) 0.45 (2.9)#
Non-dominant hand 41.43 (8.1) 0.48 (3.3)# 42.98 (7.9) 0.47 (3.9)# 41.66 (6.8) 1.05 (2.5#)
Visual reaction time (ms)
Dominant hand 394.6 (126.7) 20.5 (85.5)" 379.2 (108.0) 7.0 (67.3)" 362.0 (76.4) 13.4 (48.2)"
Non-dominant hand 431.2 (184.5) 16.4 (96.6)" 391.3 (104.0) 5.6 (66.3)# 366.4 (86.8) 23.2 (81.1)#
Mental information, processing speed and attention
Mean binary choice reaction time (ms) 406.3 (186.5) 21.4 (113.3)" 416.0 (215.3) 30.6 (181.5)" 402.1 (138.2) 41.4 (105.5)"
Computerised visual searching task (s) 19.9 (12.5) 3.9 (7.1)" 16.7 (8.8) 1.8 (3.8)" 14.7 (3.4) 0.1 (3.0)"
Memory and learning
Word recognitiona 17.0 (4.0) 0.7 (3.7)# 17.5 (3.8) 0.6 (3.0)# 18.4 (3.8) 0.4 (4.0)"
Figure recognitionb 11.9 (3.6) 1.4 (3.6)# 13.0 (3.4) 1.7 (3.3)# 12.9 (4.3) 1.0 (4.7)#
Rey AVLT immediate recall b 45.6 (12.4) 1.2 (7.3)" 45.5 (12.5) 0.7 (9.5)" 43.5 (10.6) 1.3 (9.8)"
Rey AVLT delayed recall b 10.6 (3.2) 0.3 (2.8)# 10.5 (2.9) 0.2 (1.6)# 10.0 (3.2) 0.8 (3.1)#
AVLT = auditory verbal learning test. Evaluable patients were those with observations at both baseline and end point. " and # indicates a trend towards improvement or deterioration
respectively, based on the mean change from baseline for each cognitive variable–—differences were not statistically significant.
a Carbamazepine, n = 23; valproate, n = 23.
b Carbamazepine, n = 25.
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Table 4 Analysis of intelligence test (per-protocol population)
Oxcarbazepine
(n = 45)
Carbamazepine/
valproate (n = 45)
Carbamazepine
(n = 24)
Valproate
(n = 21)
Number of correct answers: change from baseline
Mean (S.D.) 2.2 (5.20) 3.3 (4.10) 3.0 (4.02) 3.7 (4.27)
Median 2 2 2 3
Range 9—14 5—11 4—11 5—11
Changes from baseline were not statistically significant. For seven patients in the per-protocol population, either baseline and/or end
of study assessments were not performed, thus the change from baseline values are missing.‘good’ or ‘very good’, as did 77% of investigators,
73% of patients, and 80% of parents/carers in the
combined carbamazepine/valproate group. This
high rate of treatment satisfaction was also
reflected by the low dropout rate of 12%, which
was lower than the assumed 40%.
Safety and tolerability
The most frequently reported treatment-emergent
adverse events (>10%) were fatigue and headache
for oxcarbazepine, fatigue and rash for carbamaze-
pine, and headache, increased appetite and alope-
cia for valproate (Table 5). Adverse events
suspected to be drug related occurred in 30.9% of
patients in the oxcarbazepine, 28.6% in the carba-
mazepine group, and 44.8% in the valproate group.
One serious adverse event was reported for each
treatment group: oxcarbazepine, activation of
focus in EEG; carbamazepine, skin rash; and valpro-
ate, prolonged sedative effect. All serious adverse
events were mild in severity and considered by theTable 5 Most frequent adverse events (5% in any treatme
the open-label treatment phase
Adverse event No. of patients (%)
Oxcarbazepine (n = 55
Any adverse events 31 (56.4)
Fatigue 7 (12.7)
Headache 6 (10.9)
Rash NOS 4 (7.3)
Dizziness 4 (7.3)
Appetite increased NOS 2 (3.6)
Pyrexia 2 (3.6)
Rhinitis NOS 1 (1.8)
Abdominal pain NOS 1 (1.8)
Respiratory tract infection NOS 1 (1.8)
Pharyngitis 1 (1.8)
Alopecia 0 (0)
Psychomotor activity 0 (0)
Sedation 0 (0)
Influenza 0 (0)
Weight increased 0 (0)
NOS = not otherwise specified.investigators to be unrelated to the study drugs. One
patient each in the oxcarbazepine and carbamaze-
pine treatment groups experienced an adverse
event that led to treatment discontinuation, in both
cases due to skin rash. In addition, one patient in the
oxcarbazepine group discontinued treatment after
a serious adverse event (activation of focus in EEG),
which was classed as being due to unsatisfactory
therapeutic effect.Discussion
Although individual sensitivity may lead to severe
cognitive effects in individual cases, most studies
have not found clinically relevant effects of stan-
dard AED therapy (such as carbamazepine and
valproate) in study populations.2,6 Therefore, it is
important to compare the cognitive effects of any
new AED against standard agents in an equivalence
design. This study was formally not an equivalence
study, since the sample size for such a study wouldnt group, sorted by frequency in oxcarbazepine) during
) Carbamazepine (n = 28) Valproate (n = 29)
17 (60.7) 17 (58.6)
4 (14.3) 2 (6.9)
2 (7.1) 7 (24.1)
3 (10.7) 0 (0)
0 (0) 0 (0)
1 (3.6) 3 (10.3)
0 (0) 2 (6.9)
1 (3.6) 2 (6.9)
2 (7.1) 2 (6.9)
2 (7.1) 1 (3.4)
0 (0) 2 (6.9)
1 (3.6) 3 (10.3)
1 (3.6) 2 (6.9)
1 (3.6) 2 (6.9)
0 (0) 2 (6.9)
0 (0) 2 (6.9)
678 F. Donati et al.have been unreasonably high, but was powered in
order to detect an eventually clinically meaningful
difference between the treatment groups. The study
presented here was conducted to evaluate system-
atically the effects of oxcarbazepine on cognitive
functions in children aged 6 to<17 years with partial
seizures. The results indicate that oxcarbazepine
monotherapyover 6monthsdoes notadversely affect
cognitive function and intelligence in children or
adolescents with newly diagnosed partial seizures
relative to standard AED therapy; no differential
effects were observed between treatment groups
and none of the tests showed a deterioration of
cognitive function after the 6-month treatment per-
iod relative to the untreated baseline measurements
in this patient population. These results confirm
previous findings from smaller studies in adult
patients with epilepsy and healthy volunteers, which
indicated that oxcarbazepine was not associated
with cognitive impairment or intelligence, learning
and memory, attention, psychomotor speed, verbal
span, and visuospatial construction.18—21
This is the first well-controlled and adequately
powered study to investigate cognitive function in
children receiving oxcarbazepine using a fully vali-
dated cognitive function test battery. The study was
powered to detect not only a statistically significant
difference, but also a clinically meaningful differ-
ence in the primary cognitive variable of mental
processing speed (CVST). As standard AEDs are avail-
able for treatment initiation in children with partial
epilepsy, an active-control design was chosen to
evaluate the effects of oxcarbazepine relative to
standard antiepileptic monotherapy. Although the
open-label design of this study may be criticised,
this was acceptable in our opinion because the
primary and secondary cognitive outcome assess-
ments were based on an objective measurement
(computerised testing). In addition, we believe that
this approach has contributed significantly to the
extremely low dropout rate (11.6%) observed in the
study. Furthermore, the treatment duration of 6
months in previously untreated children and
adolescents with partial seizures was considered
of appropriate length to discover any possible
cognitive deterioration associated with AED therapy
over time. Indeed, the relatively long duration of
this study (6 months’ treatment), the use of an
untreated baseline in newly diagnosed patients,
and the use of AEDs as monotherapy are powerful
factors in the design of this study.
To control the confounding effects of seizures on
cognitive function during baseline, only those
patients with two or fewer secondarily generalised
partial seizures occurring within the 3 months
preceding the study were included. Nonethelessseizure effects during the study may be a confound-
ing factor. Seizures were well controlled throughout
the study, with >50% of patients being seizure free
during the 6-month treatment period, which is in
line with other comparative studies of oxcarbaze-
pine in newly diagnosed patients.10,15,31,32 None of
the comparisons between the study groups yielded
statistically significant differences in the efficacy
parameters. Thus, seizure frequency was not a
potential interfering factor that may have con-
founded our results. Indeed, the valproate group
had fewer patients with secondarily generalised
seizures, the seizure type with most cognitive
impact. Potentially, the results could therefore be
biased positively for valproate.
All AEDs employed in the study were well toler-
ated by patients and the safety profile of oxcarba-
zepine was similar to that reported previously.10,11
Only one patient (in the oxcarbazepine group) dis-
continued therapy because of activation of focus in
their EEG. Although, carbamazepine is known to be
associated with EEG changes,33—36 only three cases
have been reported following treatment with oxcar-
bazepine.37
In conclusion, the results of this study confirmed
previous findings in adult patients and healthy
volunteers that oxcarbazepine monotherapy has
no impact on cognitive function in newly diagnosed
children and adolescents with partial seizures.
Oxcarbazepine did not differ from standard therapy
(i.e. carbamazepine and valproate) as monotherapy
over 6 months on cognitive function and intelligence
in children or adolescents with newly disgnosed
partial seizures. No impairment in cognitive func-
tion was observed in any treatment group over a 6-
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